Elanco Files 8-K on Material Agreement & Reg FD Disclosure

TL;DR

**Elanco just filed an 8-K about a big agreement, but the details are missing.**

AI Summary

Elanco Animal Health Inc. filed an 8-K on February 5, 2024, to report an "Entry into a Material Definitive Agreement" and "Regulation FD Disclosure." While the filing indicates a significant agreement, the specific details of the agreement, including names and dollar amounts, are not disclosed within this initial 8-K. This matters to investors because material agreements can significantly impact a company's future revenue, expenses, and strategic direction, but without details, the impact remains uncertain.

Why It Matters

This filing signals a potentially significant business development for Elanco, but the lack of specific details means investors are currently in the dark about its financial implications.

Risk Assessment

Risk Level: medium — The filing indicates a material agreement but provides no details, creating uncertainty about its potential positive or negative impact on the company.

Analyst Insight

A smart investor would monitor Elanco's subsequent filings (like 10-Q or another 8-K) for specific details about the "Material Definitive Agreement" to assess its potential impact on the company's financials and strategic direction before making investment decisions.

Key Players & Entities

• Elanco Animal Health Incorporated (company) — the registrant filing the 8-K
• February 5, 2024 (date) — Date of Earliest Event Reported
• 001-38661 (other) — Commission File Number
• ELAN (other) — Trading Symbol on New York Stock Exchange

Forward-Looking Statements

• Elanco will file a subsequent 8-K or 10-K/Q with more details about the material definitive agreement. (Elanco Animal Health Incorporated) — high confidence, target: Q1 2024
• The market reaction to this filing will be muted until more specific details of the agreement are disclosed. (ELAN stock price) — medium confidence, target: February 2024

FAQ

From the Filing

0001104659-24-010337.txt : 20240205 0001104659-24-010337.hdr.sgml : 20240205 20240205064033 ACCESSION NUMBER: 0001104659-24-010337 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240205 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240205 DATE AS OF CHANGE: 20240205 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elanco Animal Health Inc CENTRAL INDEX KEY: 0001739104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 825497352 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38661 FILM NUMBER: 24593898 BUSINESS ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 BUSINESS PHONE: 877-352-6261 MAIL ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 8-K 1 tm245182d1_8k.htm FORM 8-K false 0001739104 0001739104 2024-02-05 2024-02-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES   SECURITIES AND EXCHANGE COMMISSION WASHINGTON , D. C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported): February 5, 2024   Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter)   Indiana   001-38661   82-5497352 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   2500 Innovation Way Greenfield , Indiana (Address of principal executive offices)   46140 (Zip Code)   Registrant’s telephone number, including area code: ( 877 ) 352-6261   Not Applicable (Former Name or Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, no par value   ELAN   New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   ¨   Emerging growth company   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨           Item 1.01. Entry into a Material Definitive Agreement.   On February 5, 2024, Elanco Animal Health Incorporated, an Indiana corporation (“Elanco”), and Intervet International B.V., a Dutch private company with limited liability (“Buyer”), entered into an Asset Purchase Agreement (the “Agreement”). The Agreement provides that, subject to the satisfaction or waiver of certain conditions, Buyer will acquire assets from Elanco of Elanco’s aqua business (the “Business”) for approximately $1.3 billion in cas